Recombinant antibodies for the diagnosis and treatment of cancer.
The advent of recombinant antibody technology led to an enormous revival in the use of antibodies as diagnostic and therapeutic tools for fighting cancer. This review provides a brief historical sketch of the development of recombinant antibodies for the diagnosis and immunotherapy of cancer and summarizes the most significant clinical data for the best established reagents to date. It also discusses clinically relevant aspects of the use of recombinant antibodies in cancer patients.
D000818:Animals; D000906:Antibodies / Q000378:metabolism / Q000627:therapeutic use*; D000917:Antibody Formation / Q000276:immunology; D000920:Antibody-Dependent Cell Cytotoxicity / Q000276:immunology; D000951:Antigens, Neoplasm / Q000276:immunology / Q000502:physiology; D003167:Complement Activation / Q000276:immunology; D006801:Humans; D007128:Immunoglobulin Fragments / Q000235:genetics / Q000627:therapeutic use; D051379:Mice; D009369:Neoplasms / Q000175:diagnosis / Q000276:immunology / Q000628:therapy*; D019151:Peptide Library; D015202:Protein Engineering; D011956:Receptors, Cell Surface / Q000276:immunology; D011993:Recombinant Fusion Proteins / Q000493:pharmacokinetics / Q000627:therapeutic use*; D014018:Tissue Distribution
D000906:Antibodies; D000951:Antigens, Neoplasm; D007128:Immunoglobulin Fragments; D019151:Peptide Library; D011956:Receptors, Cell Surface; D011993:Recombinant Fusion Proteins